Dermatologic Conditions in Transgender Populations

This review discusses the pathogenesis and treatment of acne in transgender men on testosterone therapy and reports no new clinical results, emphasizing the need for tailored guidelines.

This study observed that androgenetic alopecia had a more significant negative impact on psychological parameters in females than males, with some differences in psychosexual outcomes based on clinical stages.

This article provides a framework for understanding hair disorders and treatment options in transgender individuals undergoing hormonal therapy and reports no new clinical results.

This updated guideline from the Endocrine Society highlights the importance of endocrinologists in providing safe and effective hormone regimens for gender-affirming care, especially for adolescents who have entered puberty.

This study assessed the use of oral finasteride in transgender men with androgenetic alopecia and found that all patients improved by one grade on the Norwood–Hamilton scale within about 5.5 months, with no significant adverse effects reported during the 16.2 months of follow-up.

This review found that combined oral contraceptives and spironolactone are effective treatments for adult acne in women, but noted that oral contraceptives increase the risk of venous thromboembolism and require individual risk assessment before use.

This review discusses the unique dermatologic needs of transgender individuals during transitioning and emphasizes the importance of accommodating care in medical settings; it reports no new clinical results.

This review discusses the hormonal and genetic factors influencing acne development, emphasizing the role of androgens and insulin signaling but reports no new clinical results.

This article reviews the hormonal pathogenesis and treatment strategies for acne vulgaris, particularly in women with severe or treatment-resistant cases, associating it with hormonal imbalances and hyperandrogenism.

Minoxidil is the only FDA-approved topical drug for treating male or female pattern hair loss, and other medications like finasteride and dutasteride can also increase hair growth.

This study found that 5% minoxidil topical foam was effective in stabilizing hair density and scalp coverage in men with moderate androgenetic alopecia over 104 weeks, with good safety and tolerability.

This study found that topical minoxidil 5% foam was effective in promoting hair growth in both the frontal and vertex scalp for men with androgenetic alopecia.

This study found that testosterone therapy in trans men increased facial and body hair growth while the prevalence and severity of acne peaked at 6 months but were primarily mild after long-term treatment.

This study found that adding topical eflornithine to hair laser treatment significantly reduced hair counts and inflammatory papules more effectively than laser therapy alone in treating pseudofolliculitis barbae.

This study found that daily oral finasteride may increase hair count and improve hair appearance assessments in men with androgenetic alopecia, but it also appears to raise the risk of sexual dysfunction.

The guideline recommends mental health involvement in diagnosing gender identity disorder and outlines hormone and surgical treatment protocols, emphasizing safety, informed consent, and long-term monitoring.

This review discusses the effects of estrogens on skin aging and highlights the potential benefits of estrogen replacement therapy and selective estrogen receptor modulators for improving skin health in postmenopausal women, but reports no new clinical findings.

This study found that 5% topical minoxidil significantly increased hair regrowth and improved psychosocial perceptions of hair loss in men with androgenetic alopecia compared to 2% topical minoxidil and placebo over 48 weeks.

This review covers the history, incidence, and treatment options for pseudofolliculitis barbae and presents new data, but reports no new clinical results.

In this study, cross-sex hormone therapy affected hair growth patterns differently, with estrogen reducing hair growth in male-to-female transsexuals and testosterone increasing it in female-to-male transsexuals; however, male typical hair diameters were not fully reached in the latter group after 12 months.

This study reported that topical 2% minoxidil solution improved hair growth compared to placebo in men with early male-pattern baldness over 24 weeks, with no significant safety issues observed.